Matrix metalloproteinases and atherosclerosis. Therapeutic aspects;Métalloprotéases matricielles et athérosclérose. Perspectives thérapeutiques

Annales de Biologie Clinique

Volumn 61, Issue 2, 2003, Pages 147-158

  Beaudeux, J L ^a   Giral, P ^a   Bruckert, E ^a   Foglietti, M J ^a   Chapman, M J ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Atherosclerosis; Extracellular matrix; Metalloproteinase; Therapeutic aspects; Tissue inhibitor of metalloproteinase

Indexed keywords

ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; BATIMASTAT; DOXYCYCLINE; DRUG DERIVATIVE; HYDROXAMIC ACID; MARIMASTAT; MATRIX METALLOPROTEINASE; METALLOPROTEINASE; ORGANIC COMPOUND; PHENYLALANINE; PRINOMASTAT; THIOPHENE DERIVATIVE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANIMAL; AORTA DISEASE; ARTERIOSCLEROSIS; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DRUG ANTAGONISM; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HUMAN; HYPERLIPIDEMIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RAT; REVIEW; RISK FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; AORTIC DISEASES; ARTERIOSCLEROSIS; CASE-CONTROL STUDIES; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DOXYCYCLINE; HUMANS; HYDROXAMIC ACIDS; HYPERLIPIDEMIAS; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; ORGANIC CHEMICALS; PHENYLALANINE; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RATS; RISK FACTORS; THIOPHENES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TISSUE INHIBITOR OF METALLOPROTEINASES;

ANIMALIA;

EID: 0242499946     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: 419-20.
2. Georges SJ. Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol 1998; 9: 413-23.
3. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough, Alpers CE. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol 1996; 148: 777-83.
4. Sukhova Gk, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-9.
5. Forget MA, Desrosiers RR, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 1999; 77: 465-80.
6. Kerrigan JJ, Mansell JP, Sandy JR. Matrix turnover. J Orthod 2000; 27: 227-33.
7. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biological activity and clinical applications. J Clin Oncol 2000; 18: 1135-49.
8. Rouis M, Dejager S, Chapman J. La matrice extracellulaire et les métalloprotéases: caractéristiques et rôles dans la rupture de la plaque d'athérome. Sang Thromb Vaiss 1996; 8: 621-8.
9. Henney AM, Ye S, Zhang B, et al. Genetic diversity in the matrix metalloproteinase family: effects on function and disease progression. Ann NY Acad Sci 2000; 902: 27-38.
10. Kirchheimer JC, Remold HG. Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 1989; 74: 1396-402.
11. Estreicher A, Wohlwend A, Belin D, Schleuning WD, Vassalli JD. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J Biol Chem 1989; 264: 1180-9.
12. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
13. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994; 107: 2373-9.
14. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH. Inhibtion of of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor metalloproteinase-3. Circulation 2000; 101: 296-304.
15. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002; 21: 2245-52.
16. Li Z, Li L, Zielke HR, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-8.
17. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridation. Proc Natl Acad Sci USA 1991; 88: 8154-8.
18. Galis ZS, Sukhova GK, Libby P. Microsopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 1995; 9: 974-80.
19. Carrell TWG, Burnand KG, Wells GMA, Clements JM, Smith A. Stromelysin-1 (matrix metalloproteinase-3) and tissue inhibitor of metalloproteinase-3 are overexpressed in the wall of abdominal aortic aneurysms. Circulation 2002; 105: 477-82.
20. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999; 99: 420-6.
21. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-9.
22. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 2640-7.
23. Tyagi SC, Meyer L, Schmaltz RA, Reddy HK, Voelker DJ. Proteinases and restenosis in the human coronary artery: extracellular matrix production exceeds the expression of proteolytic activity. Atherosclerosis 1995; 116: 43-57.
24. Bayes-Genis MD, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001; 345: 1022-9.
25. Beaudeux JL, Burc L, Imbert-Bismut F, et al. Serum plasma pregnancy associated protein-A: a potential marker of echogenic carotid atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2002; 23: 7-10.
26. Lindstedt L, Saarinen J, Kalkinen N, Welgus H, Kovanen PT. Matrix metalloproteinases-3, -7, and-12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A1. J Biol Chem 1999; 274: 22627-34.
27. Zhang B, Ye S, Hermann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-94.
28. De Maat MP, Jukema JW, Ye S, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83: 852-6.
29. Terashima M, Akita H, Kanazawa K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-9.
30. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol 2002; 40: 43-8.
31. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-72.
32. Noji Y, Kajinami K, Kawashiri M, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med 2001; 39: 380-4.
33. Dorent R, Beaudeux JL, Tezenas S, et al. Circulating levels of matrix metalloproteinases in heart transplant recipients. Transplant Proc 2000; 32: 2750-1.
34. Jackson C, Nguyen M, Arkell J, Sambrook P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis - targetting gelatinase A activation. Inflamm Res 2001; 50: 183-6.
35. Chantrain C, DeClerck YA. Les métalloprotéases matricielles et leurs inhibiteurs synthétiques dans la progression tumorale. Med Sci 2002; 18: 565-75.
36. D'Armiento J. Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction. Trends Cardiovasc Med 2002; 12: 97-101.
37. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardinal infarction: a new approach to prevent heart failure? Circ Res 2001; 89: 201-10.
38. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
39. Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999; 29: 884-93.
40. 2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100: 48-54.
41. Nagase H, Brew K. Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics. Arthritis Res 2002; 4 (Suppl. 3): S51-61.
42. Dollery CM, Humphries SE, Mc Clelland A, Latchman DS, McEwan JR. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 1999; 99: 3199-205.
43. Rouis M, Adamy C, Duverger N, et al. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-I reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation 1999; 100: 533-40.
44. Hu Y, Baker AH, Zou Y, Newby AC, Xu Q. Local gene transfer of tissue inhibitor of metalloproteinase-2 influences vein graft remodeling in a mouse model. Arterioscler Thromb Vasc Biol 2001; 21: 1275-80.
45. Bigatel DA, Elmore JR, Carey DJ, Cizmeci-Smith G, Franklin DP, Youkey JR. The matrix metalloproteinase inhibitor BB-94 limits expansion of experimental abdominal aortic aneurysms. J Vasc Surg 1999; 29: 130-9.
46. Treharne GD, Boyle JR, Goodall S, Loftus IM, Bell PR, Thompson MM. Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease. Br J Surg 1999; 86: 1053-8.
47. Loftus IM, Porter K, Peterson M, et al. MMP inhibition reduces intimal hyperplasia in a human vein graft stenosis model. Ann NY Acad Sci 1999; 878: 547-50.
48. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23: 336-46.
49. Thompson RW, Baxter BT. MMP inhibition in abdominal aortic aneurysms. Rationale for a prospective randomized clinical trial. Ann NY Acad Sci 1999; 878: 159-78.
50. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87: 1451-8.
51. Plehn JF, Davis BR, Sacks FM, et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the cholesterol and recurrent events (Care) study. The Care Investigators. Circulation 1999; 99: 216-23.
52. Ballantyne CM, Herd JA, Ferlic LL, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99: 736-43.
53. Corti R, Fayad ZA, Fuster V, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, non-invasive magnetic resonance imaging. Circulation 2001; 104: 249-52.
54. Porter KE, Turner NA. Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 2002; 30: 120-6.
55. Ganne F, Vasse M, Beaudeux JL, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytes: a possible protective mechanism against atherothrombosis. Thromb Haemost 2000; 84: 680-8.
56. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103: 926-33.
57. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced aneurysm formation in mice with activation of the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) gene. Circ Res 2002; 90: 897-903.
58. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001; 21: 1440-5.
59. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J. ApoE knockout mice expressing human matrix metallo-proteinase-I in macrophages have less advanced atherosclerosis. J Clin Invest 2001; 107: 1227-34.
60. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-62.